Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Jun 22;11(6):679.
doi: 10.3390/genes11060679.

Pharmacogenomics and Personalized Medicine

Erika Cecchin  1 , Gabriele Stocco  2
Affiliations
Editorial

Pharmacogenomics and Personalized Medicine

Erika Cecchin et al. Genes (Basel). .

Abstract

Pharmacogenomics is one of the emerging approaches to precision medicine, tailoring drug selection and dosing to the patient's genetic features. In recent years, several pharmacogenetic guidelines have been published by international scientific consortia, but the uptake in clinical practice is still poor. Many coordinated international efforts are ongoing in order to overcome the existing barriers to pharmacogenomic implementation. On the other hand, existing validated pharmacogenomic markers can explain only a minor part of the observed clinical variability in the therapeutic outcome. New investigational approaches are warranted, including the study of the pharmacogenomic role of the immune system genetics and of previously neglected rare genetic variants, reported to account for a large part of the inter-individual variability in drug metabolism. In this Special Issue, we collected a series of articles covering many aspects of pharmacogenomics. These include clinical implementation of pharmacogenomics in clinical practice, development of tools or infrastractures to support this process, research of new pharmacogenomics markers to increase drug efficacy and safety, and the impact of rare genetic variants in pharmacogenomics.

Keywords: human genetics; personalized medicine; pharmacogenomics; pharmacology.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Van Der Wouden C.H., Bohringer S., Cecchin E., Cheung K.-C., Davila-Fajardo C.L., Deneer V.H.M., Dolzan V., Ingelman-Sundberg M., Jonsson S., O Karlsson M., et al. Generating evidence for precision medicine: Considerations made by the Ubiquitous Pharmacogenomics Consortium when designing and operationalizing the PREPARE study. Pharmacogenet. Genom. 2020 doi: 10.1097/FPC.0000000000000405. - DOI - PMC - PubMed
    1. Relling M.V., Klein T.E., Gammal R.S., Whirl-Carrillo M., Hoffman J.M., Caudle K.E. The Clinical Pharmacogenetics Implementation Consortium: 10 Years Later. Clin. Pharmacol. Ther. 2019;107:171–175. doi: 10.1002/cpt.1651. - DOI - PMC - PubMed
    1. Chenoweth M.J., Giacomini K.M., Pirmohamed M., Hill S.L., Van Schaik R.H.N., Schwab M., Shuldiner A.R., Relling M.V., Tyndale R.F. Global Pharmacogenomics Within Precision Medicine: Challenges and Opportunities. Clin. Pharmacol. Ther. 2019;107:57–61. doi: 10.1002/cpt.1664. - DOI - PMC - PubMed
    1. Dugo M., Devecchi A., De Cecco L., Cecchin E., Mezzanzanica D., Sensi M., Bagnoli M. Focal Recurrent Copy Number Alterations Characterize Disease Relapse in High Grade Serous Ovarian Cancer Patients with Good Clinical Prognosis: A Pilot Study. Genes. 2019;10:678. doi: 10.3390/genes10090678. - DOI - PMC - PubMed
    1. Zazuli Z., Otten L.S., Drogemoller B., Medeiros M., Monzon J.G., Wright G.E.B., Kollmannsberger C.K., Bedard P.L., Chen Z., Gelmon K.A., et al. Outcome Definition Influences the Relationship Between Genetic Polymorphisms of ERCC1, ERCC2, SLC22A2 and Cisplatin Nephrotoxicity in Adult Testicular Cancer Patients. Genes. 2019;10:364. doi: 10.3390/genes10050364. - DOI - PMC - PubMed

Publication types

LinkOut - more resources